Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
Ceftaroline fosamil with L-arginine sterile injection is a potent intravenous antibiotic formulation designed to combat serious bacterial infections, particularly those caused by methicillin-resistant *Staphylococcus aureus* (MRSA). This combination product integrates ceftaroline fosamil, a novel fifth-generation cephalosporin prodrug, with L-arginine as a stabilizing agent. The molecular formula of the active moiety, ceftaroline fosamil, is C20H25N6O7PS3, though the specific salt form may vary slightly depending on the counter-ion used in the final pharmaceutical preparation. While ceftaroline fosamil itself does not possess a single unique CAS number due to its prodrug nature and variable salt forms, the parent compound ceftaroline is often associated with CAS 849191-68-2. The addition of L-arginine serves a critical pharmaceutical function by adjusting the pH and enhancing the chemical stability of the solution, ensuring the drug remains effective throughout its shelf life and during administration.
The primary therapeutic application of this injectable solution is the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Its unique mechanism of action involves high-affinity binding to penicillin-binding protein 2a (PBP2a), which is responsible for beta-lactam resistance in MRSA strains. Unlike earlier generations of cephalosporins, ceftaroline effectively targets these resistant pathogens, making it a vital tool in modern antimicrobial stewardship programs. Clinicians administer this sterile solution via slow intravenous infusion over approximately thirty minutes. The inclusion of L-arginine ensures the solution maintains optimal solubility and prevents degradation, facilitating safe delivery to patients with severe infections. This formulation represents a significant advancement in infectious disease management, offering a targeted approach against multidrug-resistant organisms where other antibiotics have failed. By combining a broad-spectrum beta-lactam with essential excipients, manufacturers provide a reliable, stable, and highly effective treatment option for hospitalized patients requiring urgent care for complex bacterial infections.